單株抗體藥物是利用抗體的專一性標的攻擊特定細胞或蛋白質，目前已成功應用在諸如癌症與阿茲海默症等多種疾病的臨床治療。生物相似性抗體藥物則是在單株抗體藥物專利到期後，其他藥廠或生技公司參照現有公開資料所製作出的類似藥物，具有類似於該對照專利藥品的臨床療效與生物安全特性。
| Cat. No. |
Product Name |
Sensitivity (ng/ml) |
Detection Range (ng/ml) |
ab237641
|
Adalimumab ELISA Kit (Humira®) |
10 |
30 - 1000
|
| ab237669 |
Avelumab ELISA Kit (Bavencio®) |
30 |
100 - 3000 |
| ab237642 |
Bevacizumab ELISA Kit (Avastin®) |
30 |
30 - 1000 |
| ab237648 |
Cetuximab ELISA Kit (Erbitux®) |
100 |
100 - 3000 |
| ab237649 |
Denosumab ELISA Kit (Prolia®) |
3 |
3 - 300 |
| ab237643 |
Etanercept ELISA Kit (Enbrel®) |
100 |
100 - 3000 |
| ab237646 |
Golimumab ELISA Kit (Simponi®) |
100 |
100 - 3000 |
| ab237644 |
Infliximab ELISA Kit (Remicade®) |
30 |
100 - 3000 |
| ab237647 |
Infliximab ELISA Kit (Remsima®) |
30 |
100 - 3000 |
| ab237653 |
Ipilimumab ELISA Kit (Yervoy®) |
10 |
10 - 1000 |
| ab237651 |
Nivolumab ELISA Kit (Opdivo®) |
10 |
30 - 3000 |
| ab237650 |
Omalizumab ELISA Kit (Xolair®) |
10 |
30 - 1000 |
| ab237652 |
Pembrolizumab ELISA Kit (Keytruda®) |
10 |
30 - 1000 |
| ab237640 |
Rituximab ELISA Kit (Mabthera®) |
3 |
3 - 300 |
| ab237645 |
Trastuzumab ELISA Kit (Herceptin®) |
11 |
11 - 300 |
抗藥物抗體是治療用抗體進入生物體內後刺激引發免疫反應所產生的非預期性抗體。抗藥物抗體的存在不僅會降低治療用抗體的療效，更有可能導致自體免疫反應等副作用的產生。監測生物體內的抗藥物抗體含量，是評估治療用抗體是否引發個體不良藥物反應的重要參考依據。
| Cat. No. |
Product Name |
Sensitivity (ng/ml) |
Detection Range (ng/ml) |
ab237657
|
Anti-Adalimumab ELISA Kit (Humira®) |
30 |
62 - 500
|
| ab237670 |
Anti-Avelumab ELISA Kit (Bavencio®) |
Qualitative |
Qualitative |
| ab237658 |
Anti-Bevacizumab ELISA Kit (Avastin®) |
30 |
62 - 500 |
| ab237660 |
Anti-Cetuximab ELISA Kit (Erbitux®) |
30 |
62 - 500 |
| ab237663 |
Anti-Denosumab ELISA Kit (Prolia®) |
Qualitative |
Qualitative |
| ab237661 |
Anti-Etanercept ELISA Kit (Enbrel®) |
Qualitative |
Qualitative |
| ab237668 |
Anti-Filgrastim ELISA Kit (Neupogen®) |
3 |
3.1 - 50 |
| ab237662 |
Anti-Golimumab ELISA Kit (Simponi®) |
Qualitative |
Qualitative |
| ab237656 |
Anti-Infliximab ELISA Kit (Remicade®) |
15 |
62 - 500 |
| ab237659 |
Anti-Infliximab ELISA Kit (Remsima®) |
30 |
62 - 500 |
| ab237667 |
Anti-Ipilimumab ELISA Kit (Yervoy®) |
Qualitative |
Qualitative |
| ab237665 |
Anti-Nivolumab ELISA Kit (Opdivo®) |
Qualitative |
Qualitative |
| ab237664 |
Anti-Omalizumab ELISA Kit (Xolair®) |
Qualitative |
Qualitative |
| ab237666 |
Anti-Pembrolizumab ELISA Kit (Keytruda®) |
Qualitative |
Qualitative |
| ab237654 |
Anti-Rituximab ELISA Kit (Mabthera®) |
30 |
62 - 500 |
| ab237655 |
Anti-Trastuzumab ELISA Kit (Herceptin®) |
30 |
62 - 500 |
單株抗體藥物為目前藥物開發市場主流，
